GO:0008023 transcription elongation factor complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008023 defines any protein complex that interacts with RNA polymerase II to increase or reduce the rate of transcription elongation.
• The positive transcription elongation factor b (P-TEFb) is the master regulator of transcription elongation and a core component of this ontology term.
• The super elongation complex (SEC) allosterically stimulates RNA polymerase II and is frequently hijacked in cancer and HIV.
• Transcription elongation factors are conserved across eukaryotes and even bacteria, with NusG regulating pausing in Escherichia coli.
• Dysregulation of elongation factor complexes is linked to human diseases including cancer, HIV, and developmental disorders.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect the causal roles of these complexes.
Description
The transcription elongation factor complex (GO:0008023) is a cellular component defined as any protein complex that interacts with RNA polymerase II to increase (positive transcription elongation factor) or reduce (negative transcription elongation factor) the rate of transcription elongation. This term captures a diverse set of multiprotein assemblies that control the processivity and speed of RNA polymerase II as it synthesizes mRNA, thereby influencing gene expression programs critical for development, differentiation, and stress responses. Researchers study this term because elongation is a major regulatory checkpoint, and its misregulation is associated with diseases such as cancer and HIV. The positive transcription elongation factor b (P-TEFb), composed of CDK9 and cyclin T, is the best-characterized member and serves as a paradigm for the entire class. Beyond P-TEFb, the super elongation complex (SEC) and the Paf1 complex are key examples that illustrate the functional diversity within GO:0008023. Understanding the composition, assembly, and regulation of these complexes is essential for developing targeted therapies that modulate transcription elongation.
transcription elongation factor complex At A Glance
| GO ID | GO:0008023 |
|---|---|
| GO term | transcription elongation factor complex |
| Ontology | cellular_component |
| Synonym | none |
| Major function | Interacts with RNA polymerase II to increase or reduce the rate of transcription elongation |
| Major components | P-TEFb (CDK9/cyclin T), super elongation complex (SEC), Paf1 complex, NusG in bacteria |
| Conservation | Eukaryotic and bacterial (e.g., NusG in E. coli) |
| Disease relevance | Cancer, HIV, developmental disorders |
What Is GO:0008023?
In our own words, GO:0008023 refers to any protein complex that physically interacts with RNA polymerase II to either stimulate (positive transcription elongation factor) or inhibit (negative transcription elongation factor) the rate at which the polymerase extends the growing RNA transcript. This definition encompasses complexes that act directly on the polymerase or its associated factors to modulate elongation efficiency, often in response to cellular signals.
Why Is transcription elongation factor complex Important in Cell Biology?
Transcription elongation factor complexes are central to the regulation of gene expression because they determine the rate and processivity of RNA polymerase II, thereby controlling the output of thousands of genes. Their importance is underscored by their frequent dysregulation in human diseases, including cancer and HIV, where aberrant elongation drives oncogenic transcription or viral replication. Moreover, elongation factors are conserved across evolution, from bacteria to humans, highlighting their fundamental role in cellular physiology. Studying GO:0008023 provides insights into basic mechanisms of gene regulation and offers therapeutic opportunities for targeting transcription in disease.
• Controls the rate of mRNA synthesis for most protein-coding genes.
• P-TEFb is the master regulator of transcription elongation and a validated drug target.
• The super elongation complex (SEC) is frequently hijacked in leukemia and other cancers.
• HIV relies on P-TEFb and SEC for efficient viral transcription.
• Mutations in elongation factors are linked to developmental disorders and neurodegeneration.
• Bacterial NusG regulates transcription pausing and is a model for conserved elongation mechanisms.
• Elongation factors are attractive targets for small-molecule inhibitors in oncology.
• CRISPR screens have identified elongation factors as vulnerabilities in multiple cancer types.
• Understanding elongation complexes aids in the design of gene-editing strategies that require efficient transcription.
• Elongation control is critical for rapid gene expression changes during stress and immune responses.
Structure and Composition of transcription elongation factor complex
P-TEFb: The Master Regulator
In simple terms: P-TEFb is the main switch that tells RNA polymerase II to keep going.
P-TEFb is a heterodimer of CDK9 and a cyclin T subunit that phosphorylates the carboxyl-terminal domain (CTD) of RNA polymerase II and negative elongation factors, thereby promoting processive elongation. It is the most studied positive transcription elongation factor and is essential for the transition from promoter-proximal pausing to productive elongation.
Super Elongation Complex (SEC)
In simple terms: SEC is a larger assembly that boosts elongation and is often hijacked in cancer.
The SEC is a multiprotein complex that includes P-TEFb along with additional subunits such as ELL, AFF4, and ENL/AF9. It allosterically stimulates RNA polymerase II and is recruited to genes by transcription factors, playing critical roles in development and disease.
Paf1 Complex
In simple terms: The Paf1 complex is a conserved elongation factor that also works with RNA polymerase I.
The Paf1 complex is a conserved transcription elongation factor for eukaryotic RNA polymerase I and II, and recent high-resolution sequencing has revealed its broad role in elongation. It associates with the polymerase and coordinates histone modifications during elongation.
Bacterial NusG
In simple terms: NusG is a bacterial elongation factor that controls pausing.
NusG is a ubiquitous bacterial elongation factor that regulates transcription pausing by interacting with RNA polymerase and ribosomes, demonstrating the evolutionary conservation of elongation control mechanisms.
Negative Elongation Factors
In simple terms: Some complexes slow down or pause RNA polymerase II.
Negative elongation factors such as DSIF and NELF interact with RNA polymerase II to induce promoter-proximal pausing, which is later reversed by P-TEFb. These complexes are integral to the dynamic regulation of elongation.
Key Genes Involved in GO:0008023 transcription elongation factor complex
The following genes encode core components and regulators of transcription elongation factor complexes, with their major roles and research relevance.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CDK9 | Catalytic subunit of P-TEFb; phosphorylates RNA Pol II CTD | Master regulator of elongation; drug target in cancer and HIV |
| CCNT1 | Cyclin T1; regulatory subunit of P-TEFb | Required for P-TEFb activity; implicated in HIV transcription |
| CCNT2 | Cyclin T2; alternative P-TEFb subunit | Modulates P-TEFb function in specific contexts |
| AFF4 | Scaffold subunit of SEC | Frequently translocated in leukemia; oncogenic driver |
| ELL | Elongation factor in SEC | Stimulates Pol II elongation; linked to leukemia |
| ENL | Reader of acetylated histones in SEC | Oncogenic role in leukemia; target for inhibitors |
| AF9 | Component of SEC; histone reader | Involved in leukemogenesis |
| PAF1 | Component of Paf1 complex | Conserved elongation factor; links to Pol I and Pol II |
| CTR9 | Component of Paf1 complex | Regulates elongation and histone modifications |
| LEO1 | Component of Paf1 complex | Plays role in elongation and mRNA processing |
| CDC73 | Component of Paf1 complex | Tumor suppressor; mutations in hyperparathyroidism |
| NUSG | Bacterial elongation factor | Regulates pausing; model for conserved mechanisms |
| DSIF (SUPT4H1/SUPT5H) | Negative elongation factor | Induces promoter-proximal pausing |
| NELF (NELFA/B/C/D/E) | Negative elongation factor | Maintains paused Pol II |
| BRD4 | Recruits P-TEFb to chromatin | Therapeutic target in cancer and inflammation |
| MED26 | Recruits SEC to promoters | Links Mediator to elongation control |
| HIV Tat | Viral protein that hijacks P-TEFb | Essential for HIV transcription; drug target |
How Is transcription elongation factor complex Regulated?
Transcription elongation factor complexes are regulated at multiple levels, including post-translational modifications, subunit availability, and recruitment by sequence-specific transcription factors. For example, P-TEFb activity is controlled by its association with the 7SK snRNP, which sequesters it in an inactive state until released by signals that trigger elongation. The SEC is recruited to genes by factors such as MED26 and HIV Tat, which coordinate its assembly and function. Additionally, phosphorylation of RNA polymerase II CTD by CDK9 is a key regulatory event that couples elongation to mRNA processing. Bacterial NusG is regulated by interactions with ribosomes and other factors, illustrating conserved control mechanisms.
transcription elongation factor complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AFF4 | Acute leukemia | Knockout in leukemia cell lines; xenograft models |
| CDK9 | Cancer, HIV | Point mutation of kinase domain; overexpression in T cells |
| ENL | Leukemia | Knock-in of reader domain mutations; CRISPR KO |
| CDC73 | Hyperparathyroidism-jaw tumor syndrome | Knockout in parathyroid cells |
| NUSG | Bacterial pathogenesis | Bacterial knockout and point mutation |
Cancer
Dysregulation of transcription elongation factor complexes is a hallmark of many cancers. The SEC is frequently involved in chromosomal translocations in acute leukemias, leading to aberrant expression of oncogenes such as MYC and HOX genes. P-TEFb is also overactive in various malignancies, and CDK9 inhibitors are being developed as anticancer therapeutics. Targeting elongation factors has emerged as a promising strategy for oncogenic transcription-driven tumors.
HIV and Viral Infections
HIV relies on the host P-TEFb and SEC to transcribe its genome. The viral Tat protein recruits P-TEFb to the HIV promoter, and SEC promotes early HIV transcription. This dependency makes elongation factors attractive targets for antiviral therapy, and small-molecule inhibitors of P-TEFb are under investigation.
Developmental Disorders and Neurodegeneration
Mutations in components of elongation factor complexes have been linked to developmental disorders and neurodegenerative diseases. For instance, defects in P-TEFb or SEC subunits can impair gene expression programs required for neuronal development and function. The broad role of elongation in human disease underscores the importance of understanding these complexes.
From transcription elongation factor complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CDK9 kinase activity drive cancer cell proliferation? | CDK9 knockout and point mutation (kinase-dead) in cancer cell lines |
| How does SEC assembly affect HIV transcription? | Knockout of AFF4 or ELL in HIV-infected cells |
| What is the role of Paf1 complex in Pol I transcription? | Knockout of PAF1 in yeast or human cells |
| Can NusG pausing regulation be uncoupled from ribosome binding? | Point mutations in NusG in E. coli |
| Does BRD4 recruitment of P-TEFb regulate oncogene expression? | BRD4 knockout or overexpression in leukemia cells |
| What are the genome-wide binding sites of SEC? | Knock-in of tagged AFF4 for ChIP-seq |
How to Study the transcription elongation factor complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Steady-state mRNA levels | Global effects of elongation factor KO |
| PRO-seq / GRO-seq | Nascent RNA and polymerase occupancy | Elongation rate and pausing |
| ChIP-seq | Genome-wide binding of elongation factors | Recruitment of SEC or P-TEFb |
| AP-MS | Protein-protein interactions | Subunit composition of complexes |
| BioID | Proximity-dependent biotinylation | Identification of transient interactors |
| CRISPR screen | Gene essentiality and fitness | Discovery of elongation factor vulnerabilities |
| Live-cell imaging | Dynamic localization of factors | Real-time recruitment to genes |
| Ribo-seq | Translated mRNA footprints | Coupling of elongation to translation |
Transcriptomics and Elongation Profiling
RNA-seq and related methods such as PRO-seq or GRO-seq measure nascent RNA and polymerase occupancy, allowing researchers to assess the impact of elongation factor perturbations on transcription genome-wide. These techniques are essential for defining the genes controlled by GO:0008023 complexes.
Proteomics and Interaction Mapping
Affinity purification coupled with mass spectrometry (AP-MS) and proximity labeling (BioID) can identify the subunit composition and interaction partners of elongation factor complexes. These approaches reveal dynamic assembly and context-specific partners.
Imaging and Live-Cell Dynamics
Fluorescence microscopy and live-cell imaging of tagged elongation factors enable visualization of their recruitment to active transcription sites and their dynamics during elongation. This helps link complex assembly to transcriptional output.
CRISPR Screens and Functional Genomics
Genome-wide CRISPR knockout screens can identify elongation factors as essential genes in specific contexts, such as cancer cell lines or viral infection. These screens provide causal evidence for the role of GO:0008023 components in disease.
How CRISPR Can Be Used to Study GO:0008023 transcription elongation factor complex
Knockout
CRISPR knockout of genes encoding elongation factor subunits, such as CDK9 or AFF4, can abolish complex function and reveal essential roles in cell proliferation and transcription. Knockout models are widely used to validate drug targets and dissect subunit-specific functions.
Point Mutation
Introducing point mutations, such as kinase-dead CDK9 or pausing-deficient NusG, allows precise interrogation of catalytic and regulatory domains without affecting complex assembly. These models are invaluable for separating enzymatic activity from scaffolding functions.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins into endogenous loci enables endogenous expression and localization studies of elongation factors. Tagged knock-in models facilitate ChIP-seq, imaging, and proteomics.
Overexpression
Overexpression of wild-type or mutant elongation factors, such as cyclin T1 or AFF4, can mimic oncogenic activation and drive aberrant transcription. These models are useful for studying gain-of-function mechanisms in cancer and HIV.
How EDITGENE Supports transcription elongation factor complex Research
Researchers studying transcription elongation factor complex-related genes often need to determine whether a candidate gene is causally involved in elongation control, disease progression, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for transcription elongation factor complex research.
Frequently Asked Questions About transcription elongation factor complex
What is GO:0008023?
GO:0008023 is the Gene Ontology term for transcription elongation factor complex, defined as any protein complex that interacts with RNA polymerase II to increase or reduce the rate of transcription elongation.
What genes are involved in transcription elongation factor complex?
Key genes include CDK9, CCNT1, AFF4, ELL, ENL, AF9, PAF1, CTR9, LEO1, CDC73, and NUSG, among others.
What is the function of P-TEFb?
P-TEFb is a positive transcription elongation factor that phosphorylates RNA polymerase II and negative elongation factors to promote processive elongation.
How is the super elongation complex (SEC) involved in cancer?
SEC is frequently translocated or overexpressed in leukemias and other cancers, driving oncogenic transcription programs.
What diseases are associated with transcription elongation factor complex dysfunction?
Diseases include cancer, HIV, developmental disorders, and neurodegeneration.
How can CRISPR be used to study transcription elongation factor complex?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to dissect the roles of specific subunits in elongation and disease.
What methods are used to study transcription elongation factor complex?
Common methods include RNA-seq, PRO-seq, ChIP-seq, AP-MS, BioID, CRISPR screens, and live-cell imaging.
Is the transcription elongation factor complex conserved in bacteria?
Yes, bacterial NusG is a conserved elongation factor that regulates transcription pausing.
What is the role of Paf1 complex in transcription?
The Paf1 complex is a conserved elongation factor for RNA polymerase I and II, coordinating histone modifications and elongation.
How does HIV hijack transcription elongation factors?
HIV Tat recruits P-TEFb and SEC to the viral promoter to stimulate efficient viral transcription.
Conclusion
The transcription elongation factor complex (GO:0008023) is a critical cellular component that governs the rate of RNA polymerase II elongation, with profound implications for gene regulation and human disease. From the master regulator P-TEFb to the super elongation complex and conserved bacterial NusG, these complexes are central to transcription control and are validated targets in cancer and HIV. Continued research using advanced CRISPR models and functional genomics will further illuminate their mechanisms and therapeutic potential.
References
- 1. Fujinaga K et al.. 2023. P-TEFb: The master regulator of transcription elongation.. Mol Cell 83(3):393-403 PMID: 36599353
- 3. Chen Y et al.. 2021. Allosteric transcription stimulation by RNA polymerase II super elongation complex.. Mol Cell 81(16):3386-3399.e10 PMID: 34265249
- 4. Wu X et al.. 2023. Targeting the super elongation complex for oncogenic transcription driven tumor malignancies: Progress in structure, mechanisms and small molecular inhibitor discovery.. Adv Cancer Res 158:387-421 PMID: 36990537
- 5. Huffines AK et al.. 2025. High-resolution Sequencing Reveals that the Paf1 Complex May be a Conserved Transcription Elongation Factor for Eukaryotic RNA Polymerase I.. J Mol Biol 437(17):169220 PMID: 40398673
- 6. Yakhnin AV et al.. 2023. Robust regulation of transcription pausing in Escherichia coli by the ubiquitous elongation factor NusG.. Proc Natl Acad Sci U S A 120(24):e2221114120 PMID: 37276387
- 7. Conaway JW et al.. 1999. Transcription elongation and human disease.. Annu Rev Biochem 68:301-19 PMID: 10872452
- 8. Kuzmina A et al.. 2017. Super elongation complex promotes early HIV transcription and its function is modulated by P-TEFb.. Transcription 8(3):133-149 PMID: 28340332
